JP2009544703A5 - - Google Patents

Download PDF

Info

Publication number
JP2009544703A5
JP2009544703A5 JP2009521795A JP2009521795A JP2009544703A5 JP 2009544703 A5 JP2009544703 A5 JP 2009544703A5 JP 2009521795 A JP2009521795 A JP 2009521795A JP 2009521795 A JP2009521795 A JP 2009521795A JP 2009544703 A5 JP2009544703 A5 JP 2009544703A5
Authority
JP
Japan
Prior art keywords
seq
amino acids
trka
item
antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009521795A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009544703A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/016589 external-priority patent/WO2008013782A2/en
Publication of JP2009544703A publication Critical patent/JP2009544703A/ja
Publication of JP2009544703A5 publication Critical patent/JP2009544703A5/ja
Pending legal-status Critical Current

Links

JP2009521795A 2006-07-24 2007-07-24 Ｓｐ３５またはＴｒｋＡアンタゴニストの投与により髄鞘形成、ニューロンの生存および希乏突起膠細胞の分化を促進するための方法 Pending JP2009544703A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83258606P 2006-07-24 2006-07-24
US83665206P 2006-08-10 2006-08-10
PCT/US2007/016589 WO2008013782A2 (en) 2006-07-24 2007-07-24 Methods for promoting myelination, neuronal survival and oligodendrocyte differentiation via administration of sp35 or trka antagonists

Publications (2)

Publication Number Publication Date
JP2009544703A JP2009544703A (ja) 2009-12-17
JP2009544703A5 true JP2009544703A5 (https=) 2010-09-09

Family

ID=38982011

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009521795A Pending JP2009544703A (ja) 2006-07-24 2007-07-24 Ｓｐ３５またはＴｒｋＡアンタゴニストの投与により髄鞘形成、ニューロンの生存および希乏突起膠細胞の分化を促進するための方法

Country Status (4)

Country Link
US (1) US8642040B2 (https=)
EP (1) EP2068866A4 (https=)
JP (1) JP2009544703A (https=)
WO (1) WO2008013782A2 (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2298360A3 (en) * 2002-11-21 2011-07-13 Bayhill Therapeutics, Inc. Methods and immune modulatory nucleic acid compositions for preventing and treating disease
WO2004085648A2 (en) 2003-03-19 2004-10-07 Biogen Idec Ma Inc. Nogo receptor binding protein
PT1776136E (pt) 2004-06-24 2012-12-05 Biogen Idec Inc Tratamento de estados que envolvem desmielinização
SI1904104T1 (sl) 2005-07-08 2013-12-31 Biogen Idec Ma Inc. Protitelesa SP35 in njihova uporaba
KR20080080109A (ko) * 2005-11-04 2008-09-02 바이오겐 아이덱 엠에이 인코포레이티드 도파민성 뉴런의 신경돌기 성장 및 생존의 촉진 방법
CA2631181A1 (en) * 2005-12-02 2007-06-07 Biogen Idec Ma Inc. Treatment of conditions involving demyelination
JP2009544703A (ja) 2006-07-24 2009-12-17 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｓｐ３５またはＴｒｋＡアンタゴニストの投与により髄鞘形成、ニューロンの生存および希乏突起膠細胞の分化を促進するための方法
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
WO2009048605A1 (en) * 2007-10-11 2009-04-16 Biogen Idec Ma Inc. Methods for treating pressure induced optic neuropathy, preventing neuronal degeneration and promoting neuronal cell, survival via administration of lingo-1 antagonists and trkb agonists
CA2702630C (en) * 2007-11-08 2017-11-21 Biogen Idec Ma Inc. Use of lingo-4 antagonists in the treatment of conditions involving demyelination
US20110118340A1 (en) * 2008-02-08 2011-05-19 Muthiah Manoharan Delivery of rnai constructs to oligodendrocytes
DK2982695T3 (da) 2008-07-09 2019-05-13 Biogen Ma Inc Sammensætninger, der omfatter antistoffer mod lingo eller fragmenter deraf
US8822642B2 (en) * 2010-06-09 2014-09-02 Zymogenetics, Inc. Dimeric fusion proteins and related compositions and methods
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
JP6190723B2 (ja) 2010-12-01 2017-08-30 アルダーバイオ ホールディングス エルエルシー 抗ｎｇｆ組成物およびその使用
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9150867B2 (en) 2011-04-28 2015-10-06 Mayo Foundation For Medical Education And Research DNA aptamers for promoting remyelination
CN104470541A (zh) 2012-05-14 2015-03-25 比奥根艾迪克Ma公司 用于治疗涉及运动神经元的疾患的lingo-2拮抗剂
US9699433B2 (en) 2013-01-24 2017-07-04 Yuchen Zhou Method and apparatus to produce re-focusable vision with detecting re-focusing event from human eye
JP2018504400A (ja) 2015-01-08 2018-02-15 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． Ｌｉｎｇｏ‐１拮抗薬及び脱髄障害の治療のための使用
AU2016270373A1 (en) 2015-06-05 2018-01-04 Vertex Pharmaceuticals Incorporated Triazoles for the treatment of demyelinating diseases
US11185555B2 (en) 2016-04-11 2021-11-30 Noah James Harrison Method to kill pathogenic microbes in a patient
WO2018106646A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Aminotriazoles for the treatment of demyelinating diseases
WO2018106641A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Pyrazoles for the treatment of demyelinating diseases
WO2018106643A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Heterocyclic azoles for the treatment of demyelinating diseases
KR101878925B1 (ko) * 2017-01-25 2018-07-16 한국과학기술연구원 희소돌기아교세포 분화용 조성물 및 이를 이용한 희소돌기아교세포 분화방법
AR114110A1 (es) 2018-02-28 2020-07-22 Lilly Co Eli Anticuerpo anti-trka
WO2020072456A1 (en) * 2018-10-02 2020-04-09 Case Western Reserve University Compounds for treating myelin related disorders
WO2020118218A1 (en) 2018-12-06 2020-06-11 Mayo Foundation For Medical Education And Research Short dna aptamers and methods for promoting remyelination
CN113481204B (zh) * 2021-07-02 2022-08-12 湖南赛奥维生物技术有限公司 一种蛋白的核酸适配体、其衍生物及其应用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5219837A (en) 1990-06-21 1993-06-15 Trustees Of The University Of Pennsylvania Method of stimulating myelination of cells
US5468872A (en) 1993-09-16 1995-11-21 Cephalon, Inc. K-252a functional derivatives potentiate neurotrophin-3 for the treatment of neurological disorders
GB9402331D0 (en) 1994-02-07 1994-03-30 Univ Mcgill Nerve growth factor structural analogs and their uses
HU226980B1 (en) 1994-10-25 2010-04-28 Toyama Chemical Co Ltd Use of 1,2-ethanediol derivatives or salts thereof for the preparation of pharmaceutical compositions having nerve growth factor (nfg) potentiator activity
GB9525180D0 (en) 1995-12-08 1996-02-07 Univ Mcgill Design of hormone-like antibodies with agonistic and antagonistic fuctions
JP2000501416A (ja) 1996-04-26 2000-02-08 ユニバーシティー オブ オタワ ニューロン病を治療し予防するための、治療法および薬物のスクリーニング法
WO1997040847A1 (en) 1996-04-26 1997-11-06 University Of Ottawa Therapeutic and drug screening methods for the treatment and prevention of neuronal disease
PT912184E (pt) 1996-06-25 2002-12-31 Cephalon Inc Utilizacao de um derivado de k-252a para o tratamento de doencas do sietma nervoso central ou periferico e sobre-producao de citoquina
FR2776661B1 (fr) 1998-03-26 2002-04-05 Centre Nat Rech Scient Polypeptide immunoreactif du recepteur trka du ngf et utilisations
US7282482B2 (en) 1998-04-08 2007-10-16 The Regents Of The University Of California NGF for the prevention of demyelination in the nervous system
US7119165B2 (en) 2000-01-12 2006-10-10 Yale University Nogo receptor-mediated blockade of axonal growth
IL150566A0 (en) 2000-01-12 2003-02-12 Univ Yale Nucleic acids and polypeptides and nogo-receptor proteins
DE60123399T2 (de) 2000-01-18 2007-08-23 The Texas A & M University System, College Station Pharmazeutische zubereitungen enthaltend beta-turn peptidomimetische zyklische substanzen
BR0206985A (pt) 2001-01-29 2005-04-19 Idec Pharma Corp Anticorpos modificados e métodos de uso
AU2002327164A1 (en) 2001-01-29 2002-12-09 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
PT1534736E (pt) 2002-08-10 2010-09-07 Univ Yale Antagonistas do receptor nogo
WO2005016955A2 (en) 2003-08-07 2005-02-24 Biogen Idec Ma Inc. Nogo receptor antagonists
US6919426B2 (en) 2002-09-19 2005-07-19 Amgen Inc. Peptides and related molecules that modulate nerve growth factor activity
US20040186044A1 (en) 2002-11-06 2004-09-23 Cosgaya Jose Miguel Modulation of myelination by interaction with P75 and TRK receptors
WO2004085648A2 (en) 2003-03-19 2004-10-07 Biogen Idec Ma Inc. Nogo receptor binding protein
PT1776136E (pt) 2004-06-24 2012-12-05 Biogen Idec Inc Tratamento de estados que envolvem desmielinização
CA2576193A1 (en) 2004-08-03 2006-02-16 Biogen Idec Ma Inc. Taj in neuronal function
US8309517B2 (en) 2005-05-16 2012-11-13 Mcgill University LGI, LINGO and p75NTR family members: novel modulators of neuronal growth
SI1904104T1 (sl) 2005-07-08 2013-12-31 Biogen Idec Ma Inc. Protitelesa SP35 in njihova uporaba
EP1940460A4 (en) 2005-10-27 2009-08-12 Biogen Idec Inc OLIGOD DRO CYTEN MYELIN GLYCOPROTEIN COMPOSITIONS AND USES THEREOF
KR20080080109A (ko) 2005-11-04 2008-09-02 바이오겐 아이덱 엠에이 인코포레이티드 도파민성 뉴런의 신경돌기 성장 및 생존의 촉진 방법
CA2631181A1 (en) 2005-12-02 2007-06-07 Biogen Idec Ma Inc. Treatment of conditions involving demyelination
CN101405297A (zh) 2006-02-03 2009-04-08 惠氏公司 Lingo-1结构
WO2007098283A2 (en) 2006-02-27 2007-08-30 Biogen Idec Ma Inc. Use of antagonists of maif receptor complex molecules and neurotrophic factors for treatment of neurological diseases and disorders
JP2009544703A (ja) 2006-07-24 2009-12-17 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｓｐ３５またはＴｒｋＡアンタゴニストの投与により髄鞘形成、ニューロンの生存および希乏突起膠細胞の分化を促進するための方法
ATE502960T1 (de) 2006-11-17 2011-04-15 Novartis Ag Lingo bindende moleküle und pharmazeutische verwendung davon
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
WO2009048605A1 (en) 2007-10-11 2009-04-16 Biogen Idec Ma Inc. Methods for treating pressure induced optic neuropathy, preventing neuronal degeneration and promoting neuronal cell, survival via administration of lingo-1 antagonists and trkb agonists
US8460657B2 (en) * 2008-06-25 2013-06-11 H. Lundbeck A/S Modulation of the TrpV: Vps10p receptor system for the treatment of pain
DK2982695T3 (da) 2008-07-09 2019-05-13 Biogen Ma Inc Sammensætninger, der omfatter antistoffer mod lingo eller fragmenter deraf

Similar Documents

Publication Publication Date Title
JP2009544703A5 (https=)
JP2011500566A5 (https=)
JP2010518007A5 (https=)
US6531295B1 (en) Synthetic constructs encoding syndecan
Yamakawa et al. DSCAM: a novel member of the immunoglobulin superfamily maps in a Down syndrome region and is involved in the development of the nervous system
US6844168B1 (en) Compositions comprising polynucleotides encoding human fibroblast growth factor receptor and uses thereof
Thomas et al. Molecular cloning of the fMet-Leu-Phe receptor from neutrophils
US7205387B2 (en) Recombinant polypeptide useful for neurotrophin receptor mediated gene delivery and as neurotrophin agonist
US20090215814A1 (en) Method of inhibiting neurotrophin-receptor binding
EP4362985A1 (en) Oligonucleotide conjugates targeted to the transferrin receptor
NZ568705A (en) Methods for promoting neurite outgrowth and survival of dopaminergic neurons
Fuchs et al. Endogenous [3H] flunitrazepam binding in human embryonic kidney cell line 293
Lappi Tumor targeting through fibroblast growth factor receptors
CN114957354A (zh) 肝素五糖结构化合物
Wilkemeyer et al. Alcohol inhibition of cell adhesion in BMP‐treated NG108‐15 cells
Nakayama et al. α4 is a major acetylcholine binding subunit of cholinergic ligand affinity-purified nicotinic acetylcholine receptor from rat brains
JP2009538282A5 (https=)
US20080254023A1 (en) Treating Gliosis, Glial Scarring, Inflammation or Inhibition of Axonal Growth in the Nervous System by Modulating Eph Receptor
Karle et al. Antisense oligonucleotide to GABAA receptor γ2 subunit induces loss of neurones in rat hippocampus
US20050069537A1 (en) Survical promoting ncam binding and ncam ligand binding compounds
Ko et al. Cyclic AMP regulates basement membrane heparan sulfate proteoglycan, perlecan, metabolism in rat glomerular epithelial cells
EP4602164A2 (en) Small interfering rna targeting c3 and uses thereof
US6423827B1 (en) Limbic system-associated membrane protein
US20050075484A1 (en) Construction and use of synthetic constructs encoding syndecan
US20060024685A1 (en) Novel sequence variants of multi-drug resistance genes, MDR1 and MRP1, and recombinant cells expressing MRP1 and MDR1 for assessment of drug penetration and disposition